Press Releases

Press Releases

  1. BTG plc: close period update

  2. BTG announces positive safety and efficacy data in over 500 DC BeadM1 patients and compelling health economic data for TheraSphere

  3. BTG Announces FDA Acceptance of Wellstat Therapeutics’ New Drug Application for Uridine Triacetate as Antidote to Overexposure to Chemotherapy Drug 5-Fluorouracil (5-FU)

  4. BTG strides through Trekfest challenge for cancer charity

  5. BTG steps up to the Trekfest challenge for cancer charity

  6. Acute Pulmonary Embolism Trial (SEATTLE II) Published in the JACC: Cardiovascular Interventions

  7. Health Canada approves Varithena® (polidocanol injectable foam) for patients with varicose veins

  8. BTG plc: Annual General Meeting

  9. BTG plc: Annual Report and Accounts 2015

  10. First Patient in Singapore Treated with TheraSphere® Radioembolization Therapy

  11. BTG plc: Final Results

  12. REVOLENS study of PneumRx® endobronchial coils in severe emphysema meets primary endpoint

  13. BTG plc: close period update

  14. BTG begins sale of DC Bead® and Bead Block® directly to Physicians

  15. BTG plc launches a Level 1 ADR programme

  16. BTG plc updates revenue guidance and ceases publication of interim management statements

  17. Completion of the acquisition of PneumRx, Inc.